NextCell () | Spotlight

The Swedish market will close at 13:00 on May 13th. On May 14th, the Swedish, Norwegian and Danish markets will be closed. On May 15th the Danish market will be closed.

NextCell Pharma operates in medical technology. Today, development is carried out of stem cell products mainly used in the treatment of autoimmune diabetes and for kidney transplants. A significant part of the work consists of stem cell research where the company develops drug candidates that should enable and increase the acceptance of organ transplants. In addition, the company has a stem cell bank. The company was established in 2014 and is based in Huddinge.

Quotes for NextCell Pharma AB

+/-
%




()

Board

CEO

Mathias Svahn

Chairperson of the Board

Anders Essen-Möller

Board

Camilla Myhre Sandberg
Edvard Smith
Hans-Peter Ekre
Niclas Löwgren

Articles of association

News

2020-07-06 16:45:00 Spotlight: Market Notice 181/20 – NextCell Pharma AB will be delisted after close of the market on July 21, 2020
2020-07-06 13:01:21 NextCell approved for trading on Nasdaq First North
2020-07-06 13:00:52 NextCell godkänns för handel på Nasdaq First North
2020-06-30 15:45:00 Spotlight: Market Notice 172/20 – Last day of trading in NextCell Pharma AB’s BTA
2020-06-30 10:32:32 Sista dag för handel med BTA i NextCell Pharma AB

Analysis

2019-06-17 SvD Börsplus: Cellsynt investeringstillfälle
2018-08-19 SvD Börsplus: En revolution som kräver kapital

NextCell Pharma AB

Quotes for NextCell Pharma AB

Board

News

Analysis

Videos

NextCell Pharma Sedermeradagen Stockholm 2017

VD Mathias Svahn - HemmaHos NextCell

VD Mathias Svahn presenterar bolaget.

Annual reports, prospectus etc.